Indian Lobby Warns Of Proposed EU-India Free Trade Agreement's Impact; Says Drug Supplies Of Developing Nations May Be In Jeopardy
This article was originally published in PharmAsia News
MUMBAI - As India and the European Union draw closer to signing a comprehensive Free Trade Agreement, the Indian Pharmaceutical Alliance - an influential lobby group of leading Indian pharmaceutical companies - has appealed to the Indian government to exercise caution and abstain from giving in to EU's demands, particularly those that allegedly ask for "TRIPS plus" provisions to be incorporated in the Indian legal framework
You may also be interested in...
Disputes over EU blockades of Indian drug shipments are still on the negotiation table, says Commerce Ministry. India hopes to initiate talks with China as well.
Indian Pharma Lobby Flays India-EU Trade Talks; Debunks "TRIPS Plus" Provisions On Patent Extensions And Data Protection
MUMBAI - Hardball negotiations between Indian and European Union representatives on the signing of a free trade agreement may lead to flare ups after the Indian Pharmaceutical Alliance - a powerful industry lobby - raised strong objections on provisions related to intellectual property rights that are sought to be incorporated in the draft treaty
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).